MeSH D005909 - glioblastoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Temozolomide | Temozolomide Teva |  | 2010-01-28 |  |  |
| Ingenus | Carmustine | Carmustine |  | 2022-06-21 |  |  |
| Mylan | Bevacizumab | Abevmy |  | 2021-04-21 |  |  |
| Bevacizumab | Lextemy |  |  |  |  | |
| Temozolomide | Temozolomide |  | 2016-06-29 |  |  | |
| Carmustine | Carmustine |  | 2023-03-03 |  |  | |
| Roche | Bevacizumab | Avastin |  | 2005-01-12 | $1,987.484 M | Q4/22-Q3/23 |
| Sandoz | Temozolomide | Temozolomide Sandoz |  | 2010-03-15 |  |  |
| Merck Sharp & Dohme | Temozolomide | Temodal |  | 1999-01-26 |  |  |
| Temozolomide | Temodar |  | 1999-08-11 | $215 M | Y2018 | |
| Pfizer | Bevacizumab | Zirabev |  | 2019-06-27 | $424 M | Y2023 |
| Dr Reddys Laboratories | Carmustine | Carmustine |  | 2020-10-22 |  |  |
| Rising Pharmaceuticals | Temozolomide | Temozolomide |  | 2016-04-27 |  |  |
| Zydus Therapeutics | Temozolomide | Temozolomide |  | 2017-07-31 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
76%158/209
Phase 2
15%35/232
Phase 3
10%4/40
Approved: 2Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use